secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioCardia, Inc. (BCDA)
CIK:        0000925741
Form:       8-K
Filed at:   2026-06-18T12:00:37+00:00
Accession:  0001437749-26-021041
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCardia targets Q4 2026 Japan PMDA submission for CardiAMP cell therapy; updates on US trial and pipeline
--------------------------------------------------------------------------------

- Japan PMDA supports potential approval of CardiAMP for ischemic HFrEF; submission planned for Q4 2026.
- Initial Japan target: 20,000 patients; prior cardiac cell therapy reimbursement at $124,000 per procedure.
- CardiAMP HF II trial enrolling in US with 4 active centers; FDA may support Premarket Approval.
- Helix delivery catheter in discussions with 8 gene/cell therapy programs; allogeneic MSC platform has 2 FDA INDs.
- Recent financing closed to fund PMDA submission, US trial enrollment, and partnership discussions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/925741/000143774926021041/0001437749-26-021041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/925741/000143774926021041/bcda20260617_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-021041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer